1643.HK Modern Chinese Medicine HKSE +28.77% intraday 03 Feb 2026: watch RSI

The 1643.HK stock surged 28.77% intraday on 03 Feb 2026, trading at HK$0.94 on the HKSE in Hong Kong as volume spiked to 3,522,000.00 shares. The move lifted the share price above the 50-day average of HK$0.61 and the 200-day average of HK$0.58, signalling a breakout that traders are watching for follow-through and confirmation.

Intraday performance of 1643.HK stock

Modern Chinese Medicine Group (1643.HK) opened at HK$0.88 and hit a day high of HK$1.00 during intraday trade on 03 Feb 2026. The stock closed the observation window at HK$0.94, up HK$0.21 from the previous close of HK$0.73, on a relative volume of 6.95 versus average volume 560,836.00.

Drivers and news behind the jump for 1643.HK stock

There is no single company press release tied to this spike; the gain appears driven by heavy buying and momentum into healthcare small-caps in Hong Kong. Short-term flows and sector rotation into Drug Manufacturers – General likely amplified the move, as Healthcare peers have shown mixed performance year-to-date.

Valuation and financial metrics for 1643.HK stock

Modern Chinese Medicine shows a PE ratio of 21.75 and EPS of HK$0.04, with book value per share HK$0.81 and PB near 0.96, indicating price close to book value. The company reports a current ratio of 8.53 and minimal debt (debt-to-equity 0.00 after rounding), which supports balance-sheet strength but free cash flow metrics are negative.

Technical setup and indicators for 1643.HK stock

Momentum indicators are stretched: RSI 70.37 and CCI 249.26 suggest overbought conditions while intraday breakout above HK$1.00 is a short-term resistance test. Volume confirmed the move with 3,522,000.00 shares traded, well above the average, and MACD histogram turned slightly positive, signalling near-term bullish momentum.

Meyka AI rates 1643.HK with a score out of 100 and forecast

Meyka AI rates 1643.HK with a score out of 100: 60.38 (Grade B) — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year price of HK$0.90, a 3-year target of HK$1.42, and a 5-year target of HK$1.92. These model-based projections show a short-term implied downside of -3.77% to the 1-year target from the current HK$0.94, and multi-year upside of 50.60% (3-year) and 104.60% (5-year); forecasts are model-based projections and not guarantees.

Risks and catalysts for 1643.HK stock

Key risks include low free cash flow, negative operating cash flow per share (approx -HK$0.01), and sensitivity to sentiment in small-cap healthcare names. Catalysts that could extend gains include better-than-expected earnings updates, distribution deals, or sector rotation into domestically focused Chinese drugmakers.

Final Thoughts

1643.HK stock posted a strong intraday rally to HK$0.94 on 03 Feb 2026, up 28.77%, driven by heavy volume and momentum in the healthcare sector on the HKSE. Valuation metrics show a PE of 21.75 and PB near 0.96, while the balance sheet remains healthy with a current ratio of 8.53 and negligible debt. Technicals warn of overbought conditions with RSI 70.37, so traders should watch whether volume sustains above the breakout level of HK$1.00. Meyka AI’s forecast model projects HK$0.90 for one year, implying a slight downside of -3.77% from today, and longer-term upside to HK$1.42 in three years and HK$1.92 in five years; these are model outputs, not guarantees. For intraday and short-term traders the name remains high-volatility; for longer-term investors, the stock’s solid book value and low leverage support a measured HOLD stance while awaiting clearer fundamental catalysts. See the live Meyka stock page for ongoing updates: Meyka 1643.HK page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.